Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Not Yet Opened 01-22 16:00:00 EST

680.03

-7.77

-1.13%

盘后680.03

+0.000.00%

19:59 EST

High699.88	Low677.68	Vol945.29K
Open689.77	D1 Closing687.80	Amplitude3.23%
Mkt Cap73.49B	Tradable Cap72.03B	Total Shares108.07M
T/O646.97M	T/O Rate0.89%	Tradable Shares105.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":680.03,"timestamp":1737579600000,"preClose":687.8,"halted":0,"volume":945293,"hourTrading":{"tag":"盘后","latestPrice":680.03,"preClose":680.03,"latestTime":"19:59 EST","volume":55879,"amount":37999654.138,"timestamp":1737593965213},"delay":0,"floatShares":105923528,"shares":108072385,"eps":40.428474,"marketStatus":"Not Yet Opened","change":-7.77,"latestTime":"01-22 16:00:00 EST","open":689.77,"high":699.88,"low":677.68,"amount":646973323.03545,"amplitude":0.032277,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":40.428474,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1737622800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":687.8,"preHourTrading":{"tag":"盘前","latestPrice":691.98,"preClose":687.8,"latestTime":"09:28 EST","volume":779,"amount":536026.36334,"timestamp":1737556080017},"postHourTrading":{"tag":"盘后","latestPrice":680.03,"preClose":680.03,"latestTime":"19:59 EST","volume":55879,"amount":37999654.138,"timestamp":1737593965213},"volumeRatio":0.98808,"impliedVol":0.405,"impliedVolPercentile":0.9641},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2505080247","title":"RBC Capital Sticks to Their Buy Rating for Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505080247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505080247?lang=en_us&edition=fundamental","pubTime":"2025-01-23 09:58","pubTimestamp":1737597482,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) on January 21 and set a price target of $1,059.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-regeneron-regn-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-regeneron-regn-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2505747526","title":"RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,059 From $1,184, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2505747526","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505747526?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:23","pubTimestamp":1737552182,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $1,025.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2505785930","title":"REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES","url":"https://stock-news.laohu8.com/highlight/detail?id=2505785930","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505785930?lang=en_us&edition=fundamental","pubTime":"2025-01-22 03:35","pubTimestamp":1737488100,"startTime":"0","endTime":"0","summary":"Facilities for Regeneron Canada in thriving Mississauga/GTA biotech hub signal its growth and readiness to bring more of its life-transforming innovative medicines for serious diseases to Canadians. MISSISSAUGA, ON, Jan. 21, 2025 /CNW/ - Regeneron Canada Company today officially opened its first headquarters that will allow it to better serve the needs of Canadian patients who may benefit from its life-transforming, innovative medicines for serious diseases.The facility is located in the thriving biotechnology hub of Mississauga, a vital part of the important and growing sector in the Greater Toronto Area  and in Ontario as a whole.Taking part in the official opening ceremonies with leaders from Regeneron Canada and the Regeneron Global Headquarters in Tarrytown, NY, were Nina Tangri, Associate Minister of Small Business and MPP Mississauga – Streetsville, Deepak Anand, MPP for Mississauga – Malton, Brett McDermott, Director of Government and Stakeholder Relations,Mississauga Board of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-expands-presence-canada-opening-193500349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","BK4139","LU0320765992.SGD","BK4588","LU0289739699.SGD","LU2362541273.HKD","LU0889565916.HKD","LU2362541513.USD","LU0109394709.USD","LU2089984988.USD","LU1917777945.USD","LU2023250504.SGD","BK4211","LU2468319806.SGD","BK4585","LU0114720955.EUR","LU1974910355.USD","LU0882574055.USD","BY","LU0058720904.USD","LU0823416689.USD","LU2362540622.SGD","REGN","LU2237438978.USD","LU0053666078.USD"],"gpt_icon":0},{"id":"2504465786","title":"Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’","url":"https://stock-news.laohu8.com/highlight/detail?id=2504465786","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504465786?lang=en_us&edition=fundamental","pubTime":"2025-01-19 19:17","pubTimestamp":1737285459,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar.In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.  stands against the other stocks on Jim Cramer's radar.Jim Cramer, host of Mad Money, recently emphasized the importance of long-term investing, urging investors to focus on the growth prospects of certain pharmaceutical stocks while also answering callers’ questions about certain stocks. Cramer acknowledged that stocks often experience cyclical trends, with some sectors falling out of favor temporarily.“Look, stocks go in and out of style in the Wall Street fashion show. Whole sectors wallow at times. Right now, healthcare’s in some sort of doghouse the likes of which I’ve never seen.”READ ALSO Jim Cramer’s Lightning Round: 7 Stocks Under the Spotlight and Jim Cramer is Watching These 8 Stocks. A pharmacist in a lab coat carefully analyzing a vial of medicine f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-regeneron-pharmaceuticals-inc-111739382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","LU2468319806.SGD","USJW.SI","NVIW.SI","SQQQ","PSQ","TSYW.SI","QLD","LU2362540622.SGD","LU2362541513.USD","LU0882574055.USD","LU1917777945.USD","LU0823416689.USD","LU0320765992.SGD","ABIL","LU0889565916.HKD","LU2106854487.HKD",".IXIC","LU0289739699.SGD","BK4139","TQQQ","LU2023250504.SGD","LU2237438978.USD","LU1974910355.USD","USAW.SI","MDCO","BK4585","LU0058720904.USD","LU0114720955.EUR","LU0109394709.USD","LU0053666078.USD","LU2362541273.HKD","QID","REGN","MNQmain","BK4588","NQmain"],"gpt_icon":1},{"id":"2504419355","title":"U.S. Weekly Review: Stock Market Rises On Tame Inflation, Bank Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2504419355","media":"Investor’s Business Daily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504419355?lang=en_us&edition=fundamental","pubTime":"2025-01-18 10:06","pubTimestamp":1737165989,"startTime":"0","endTime":"0","summary":"The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy signals.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a39edd96196a516577c3dca2fb60dbf4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/stock-market-rises-tame-inflation-bank-earnings/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["AEO","PLNT","HEES","BBIO","URBN","NVDU","ITCI","HRMY","ELV","BAC","NVDX","LULU","AXSM","URI","REGN","CNC","LTH","SPRY","NVD","NEO","ANF","TGT","NVDD","CI","JNJ","BLK","NVDS","TSM","UNH"],"gpt_icon":1},{"id":"2504432112","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2504432112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504432112?lang=en_us&edition=fundamental","pubTime":"2025-01-18 05:42","pubTimestamp":1737150120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  shed 1.68% to $681.58 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 1.00% to 5,996.66 and the Dow Jones Industrial Average  rising 0.78% to 43,487.83.This was the stock's second consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 43.73% below its 52-week high of $1,211.20, which the company reached on August 27th.The stock underperformed when compared to some of its competitors Friday, as Amgen Inc.  rose 0.99% to $272.11, Moderna Inc.  rose 0.89% to $34.06, and Gilead Sciences Inc.  rose 0.21% to $91.84.Trading volume  eclipsed its 50-day average volume of 844,395.Data source: Dow Jones Market Data, FactSet. Data compiled January 17, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jon","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2504111570","title":"Intellia Loses 21.6% in a Week: How Should You Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504111570","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504111570?lang=en_us&edition=fundamental","pubTime":"2025-01-18 02:34","pubTimestamp":1737138840,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization.Intellia is a clinical-stage gene editing company focused on developing innovative CRISPR-based therapies. As part of the recently announced portfolio reorganization, NTLA is planning to prioritize the development of its late-stage programs — NTLA-2002 and nexiguran ziclumeran . The company will also reduce its workforce by 27% in 2025.Nexiguran ziclumeran is an investigational in vivo CRISPR-based therapy designed to inactivate the transthyretin  gene in liver cells, thereby preventing the production of TTR protein for the treatment of transthyretin  amyloidosis, a rare, progressive and fatal disease. Intellia has a collaboration agreement with Regeneron Pharmaceuticals REGN for the development and commercialization of nex-z.Nexiguran ziclumeran is being studied for two indications — ATTR amyloidosis with polyneuropathy  and ATTR amyloidosis with c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intellia-loses-21-6-week-183400659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0205194284.USD","LU1917777945.USD","HAE","LU1861559042.SGD","IE00BLDYK493.USD","LU0109394709.USD","BK4585","BK4556","LU2362541513.USD","LU0289739699.SGD","LU1974910355.USD","LU2362541273.HKD","LU0205193047.USD","LU0882574055.USD","LU1169590202.USD","LU0012050646.USD","BK4198","IE00B64QTZ34.USD","BK4139","LU2468319806.SGD","IONS","LU1169589451.USD","LU2089984988.USD","LU2106854487.HKD","NTLA","BK4535","LU0053666078.USD","LU0889565916.HKD","REGN","LU2023250504.SGD","CRSP","LU1861558580.USD","LU2362540622.SGD","LU0106261612.USD","LU0114720955.EUR","LU0823416689.USD","LU0058720904.USD","LU0320765992.SGD","BK4588","LU2237438978.USD"],"gpt_icon":0},{"id":"2504160193","title":"How to Find Strong Medical Stocks Slated for Positive Earnings Surprises","url":"https://stock-news.laohu8.com/highlight/detail?id=2504160193","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504160193?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:00","pubTimestamp":1737122412,"startTime":"0","endTime":"0","summary":"Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.The earnings figure itself is key, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb even higher.HUM is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Regeneron  as well.To read this article on Zacks.com click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strong-medical-stocks-slated-positive-140012731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REGN"],"gpt_icon":0},{"id":"2504943658","title":"Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2504943658","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504943658?lang=en_us&edition=fundamental","pubTime":"2025-01-17 01:39","pubTimestamp":1737049180,"startTime":"0","endTime":"0","summary":"Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2025/01/Stock-VeronaPharma-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/01/Stock-VeronaPharma-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/verona-pharma-stock-ohtuvayre-launch-copd-treatment/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0109394709.USD","BK4585","BK4007","LU2362540622.SGD","BK4588","LU0320765992.SGD","LU1974910355.USD","IE00BFXG1179.USD","REGN","LU2362541513.USD","BK4139","LU2468319806.SGD","LU0823416689.USD","LU0114720955.EUR","LU2237438978.USD","LU0053666078.USD","LU2089984988.USD","VRNA","LU0889565916.HKD","LU0058720904.USD","LU2362541273.HKD","LU0882574055.USD","LU2023250504.SGD","LU0289739699.SGD","LU1917777945.USD","SNY","LU2106854487.HKD"],"gpt_icon":1},{"id":"2504946880","title":"Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2504946880","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504946880?lang=en_us&edition=fundamental","pubTime":"2025-01-17 01:00","pubTimestamp":1737046800,"startTime":"0","endTime":"0","summary":"It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan Healthcare Conference. Among these, Moderna MRNA and Regeneron Pharmaceutical REGN were in the limelight on financial updates. Meanwhile, Intellia Therapeutics NTLA was down after it announced a strategic update and workforce reduction.Moderna reported preliminary product sales between $3 billion and $3.1 billion for 2024. This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia. This figure was mainly toward the lower end of the company’s previously issued guidance of $3.0-$3.5 billion. Cash, cash equivalents and investments at year-end 2024 were approximately $9.5 billion.However, Moderna cut its previously announced sales guidance for 2025 by $1 billion. It now forecasts total revenues to be in the range of $1.5-$2.5 billion, mainly from product sales of its COVID-19 and RSV vaccines. Management expects to ge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-mrna-ntla-170000544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4556","LU0823416689.USD","LU2362541273.HKD","LU0289739699.SGD","LU0234570918.USD","BK4585","IE00B19Z9Z06.USD","LU1917777945.USD","LU1861558580.USD","BK4568","LU2089984988.USD","BK4007","BK4551","LU1861559042.SGD","LU2362541513.USD","LU1829250122.USD","REGN","BK4534","IE00B19Z9P08.USD","BK4533","LU2468319806.SGD","GSK.UK","BK4139","MRNA","BIIB","LU0058720904.USD","SAGE","LU0889565916.HKD","BK4535","LU2237438978.USD","LU2106854487.HKD","LU0882574055.USD","LU2023250504.SGD","BK4501","NTLA","LU2362540622.SGD","BK4548","LU0114720955.EUR","IE00B894F039.SGD","LU0053666078.USD","BK4532","BK4588","LU0109394709.USD","LU1974910355.USD","LU0320765992.SGD","GSK"],"gpt_icon":1},{"id":"2504173059","title":"UBS cuts rating on Regeneron stock amid Eylea uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2504173059","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504173059?lang=en_us&edition=fundamental","pubTime":"2025-01-17 00:28","pubTimestamp":1737044910,"startTime":"0","endTime":"0","summary":"Investing.com --UBS has downgraded Regeneron Pharmaceuticals Inc  to \"Neutral\" from \"Buy\" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.The brokerage highlighted limited adoption of high-dose Eylea amid rising branded and biosimilar competition. UBS projects a 14% drop in Eylea revenue for 2025, with further declines in 2026.“We believe there is a disconnect between the market's shorter-term focus on Eylea revenues vs. REGN's focus on building a long-term sustainable business,” analyst said.“Eylea high dose adoptions are still limited at this stage, and with the backdrop of branded and biosimilar competition we don’t expect an inflection in the near-term.”UBS noted that the stock’s valuation, trading at 15x earnings, reflects its innovation but sees investors pivoting to peers with stronger short-term growth.Regeneron shares are trading near pre-Eylea HD approval levels, which UBS considers fair value. The volatile macro environment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ubs-cuts-rating-regeneron-stock-162830287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REGN"],"gpt_icon":0},{"id":"2503196093","title":"UBS Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Cuts Price Target to $738 From $1,130","url":"https://stock-news.laohu8.com/highlight/detail?id=2503196093","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503196093?lang=en_us&edition=fundamental","pubTime":"2025-01-16 19:46","pubTimestamp":1737027976,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $1,030.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2503960372","title":"Regeneron Pharmaceuticals Inc. Stock Rises Wednesday, Still Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2503960372","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503960372?lang=en_us&edition=fundamental","pubTime":"2025-01-16 06:20","pubTimestamp":1736979600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rallied 1.82% to $703.43 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 1.83% to 5,949.91 and the Dow Jones Industrial Average  rising 1.65% to 43,221.55.Regeneron Pharmaceuticals Inc. closed 41.92% below its 52-week high of $1,211.20, which the company reached on August 27th.The stock outperformed some of its competitors Wednesday, as Amgen Inc.  rose 0.69% to $268.94, Moderna Inc.  rose 0.90% to $34.77, and Gilead Sciences Inc.  rose 1.52% to $92.38.Trading volume  remained 118,310 below its 50-day average volume of 877,286.Data source: Dow Jones Market Data, FactSet. Data compiled January 15, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2503862272","title":"Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’","url":"https://stock-news.laohu8.com/highlight/detail?id=2503862272","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503862272?lang=en_us&edition=fundamental","pubTime":"2025-01-16 00:29","pubTimestamp":1736958541,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks.In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.  stands against the other stocks.On the topic of markets, Cramer was appreciative of the fact that the market and equal-weighted benchmark S&P indexes are up identically over the last six months \"Well look I, that's good news actually. We want to have broader leadership,\" he remarked. However, without Wall Street's favorite AI stock, Cramer believes \"you have a market that's kind of ruthless. . . David, you know that this market survives on NASDAQ fuel and not on Dow fuel. And yet people sti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-regeneron-pharmaceuticals-inc-162901501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023250504.SGD","USJW.SI","PPI","LU2362541513.USD","BK4588","LU2106854487.HKD","LU0053666078.USD","LU2362540622.SGD","TQQQ","BK4139","LU1974910355.USD","QID","LU2237438978.USD","TSYW.SI","USAW.SI","NVIW.SI","REGN","SQQQ","LU0882574055.USD","LU0889565916.HKD",".IXIC","NQmain","QLD","LU0823416689.USD","LU2468319806.SGD","BK4570","LU0114720955.EUR","MNQmain","BK4585","LU2362541273.HKD","LU0109394709.USD","LU0289739699.SGD","LU1917777945.USD","LU0320765992.SGD","LU2089984988.USD","PSQ","LU0058720904.USD"],"gpt_icon":1},{"id":"2503489306","title":"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503489306","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503489306?lang=en_us&edition=fundamental","pubTime":"2025-01-15 19:00","pubTimestamp":1736938822,"startTime":"0","endTime":"0","summary":"It is hard to get excited after looking at Regeneron Pharmaceuticals'  recent performance, when its stock has declined 31% over the past three months. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Particularly, we will be paying attention to Regeneron Pharmaceuticals'  ROE today.ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.Check out our latest analysis for Regeneron Pharmaceuticals","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-110022908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","LU1974910355.USD","USJW.SI","IE00B64PRP62.GBP","LU2210149790.SGD","LU0823416689.USD","LU2362541513.USD","QID","LU2023250504.SGD","IE00B3QW5Z07.USD","LU0114720955.EUR","LU0289739699.SGD","SQQQ","LU2362540622.SGD","LU2089984988.USD","LU2237438978.USD","BK4139","LU2106854487.HKD","REGN","LU2362541273.HKD","LU1917777945.USD","BK4588","TQQQ","NQmain","LU2210150020.SGD","NDAQ","LU2468319806.SGD","LU0882574055.USD","LU0109394709.USD",".IXIC","NVIW.SI","LU0889565916.HKD","LU0053666078.USD","QLD","TSYW.SI","BK4585","PSQ","MNQmain","USAW.SI","BK4112","LU2095319765.USD","LU0320765992.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2503636155","title":"Regeneron CEO: We have 40 drugs in development","url":"https://stock-news.laohu8.com/highlight/detail?id=2503636155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503636155?lang=en_us&edition=fundamental","pubTime":"2025-01-15 07:45","pubTimestamp":1736898313,"startTime":"0","endTime":"0","summary":"In an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in potential s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-ceo-we-have-40-drugs-in-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-ceo-we-have-40-drugs-in-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053666078.USD","LU0114720955.EUR","LU2089984988.USD","LU0823416689.USD","BK4585","LU0109394709.USD","LU2362541273.HKD","LU1974910355.USD","LU0882574055.USD","LU0289739699.SGD","LU2362540622.SGD","LU2023250504.SGD","LU1917777945.USD","LU2362541513.USD","BK4139","LU0889565916.HKD","LU2106854487.HKD","LU2237438978.USD","BK4588","LU2468319806.SGD","REGN","LU0058720904.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2503685855","title":"BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2025-01-14","url":"https://stock-news.laohu8.com/highlight/detail?id=2503685855","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503685855?lang=en_us&edition=fundamental","pubTime":"2025-01-15 03:45","pubTimestamp":1736883905,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2025-01-14Nasdaq 100 .NDXTop PerformersPercent ChangeMicrostrategy Inc MSTR.OQ+7.6%Constellation Energy Corp CEG.OQ+4.8%Atlass","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nL8N3OA1V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","IE00BJLML261.HKD","TEAM","LU0211331839.USD","REGN","LU0354030511.USD","BK4587","LU0149725797.USD","IE00BD4GTW91.USD","LU0234572021.USD","LU2552382132.HKD","LU1718418525.SGD","BK4512","LU1316542783.SGD","CDW","LU1069344957.HKD","CEG","DXCM","LU1670627923.USD","LU0354030438.USD","LU0912757837.SGD","LU2023250330.USD","LU0256863811.USD","SG9999018857.SGD","SG9999014906.USD","SG9999004303.SGD","BK4592","LU1732800096.USD","LU0157215616.USD","LU0979878070.USD","SG9999002232.USD","LU0130102774.USD","BK4141","LU0203345920.USD","META","PYPL","LU2298322129.HKD","ON","LU1720051108.HKD","MSTR","IE0009356076.USD","BIIB","LU2357305700.SGD","LU0640476718.USD","BK4534","LU1699723380.USD","LU2552382215.SGD","LU2764262908.HKD","BK4527"],"gpt_icon":1},{"id":"2503631260","title":"Regeneron Reports Eylea Sales, Provides Other Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2503631260","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503631260?lang=en_us&edition=fundamental","pubTime":"2025-01-15 02:50","pubTimestamp":1736880600,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference.Shares of the company moved up in pre-market trading on Jan. 14.Shares of REGN have plunged 33.7% in the past six months compared with the industry’s decline of 12.3%.Regeneron’s lead drug, Eylea , is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.To counter the ongoing decline in Eylea sales, Regeneron developed a higher dose  of the drug, Eylea HD.Per Regeneron, on a combined basis, Eylea 2 mg and Eylea HD maintained their leadership position in the anti-VEGF category leader in 2024 in the United States.On a preliminary basis, Eylea and Eylea HD recorded $6 billion in sales in 2024 in the United States. Sales for the fourth quarter were $1.5 billion in the United States, in line with the Zacks Consensus Estimate.Regeneron records its share of profits in connection with Eylea’s sales outside the United Sta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-reports-eylea-sales-provides-185000886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REGN"],"gpt_icon":0},{"id":"2503521498","title":"Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503521498","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503521498?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:09","pubTimestamp":1736856560,"startTime":"0","endTime":"0","summary":"In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Regeneron (REGN – Research Report), with a price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-regeneron-regn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-regeneron-regn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2503525015","title":"Regeneron (REGN) Gets a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2503525015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503525015?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:31","pubTimestamp":1736854280,"startTime":"0","endTime":"0","summary":"Bernstein analyst William Pickering maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,070.00. The co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/regeneron-regn-gets-a-buy-from-bernstein?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/regeneron-regn-gets-a-buy-from-bernstein?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0109394709.USD","LU2023250504.SGD","LU2468319806.SGD","LU1917777945.USD","LU2362541273.HKD","LU0289739699.SGD","LU0889565916.HKD","LU0058720904.USD","LU0882574055.USD","BK4585","BK4139","LU2237438978.USD","LU0053666078.USD","LU0114720955.EUR","LU2106854487.HKD","LU1974910355.USD","LU0320765992.SGD","LU2089984988.USD","LU2362540622.SGD","REGN","LU0823416689.USD","LU2362541513.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.2694},{"period":"6month","weight":-0.3537},{"period":"1year","weight":-0.2705},{"period":"ytd","weight":-0.0344}],"compareEarnings":[{"period":"1week","weight":0.0358},{"period":"1month","weight":0.0201},{"period":"3month","weight":0.0434},{"period":"6month","weight":0.1201},{"period":"1year","weight":0.2474},{"period":"ytd","weight":0.029}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.039602},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.064499},{"month":6,"riseRate":0.411765,"avgChangeRate":0.00486},{"month":7,"riseRate":0.647059,"avgChangeRate":0.053048},{"month":8,"riseRate":0.529412,"avgChangeRate":0.02165},{"month":9,"riseRate":0.470588,"avgChangeRate":0.0249},{"month":10,"riseRate":0.382353,"avgChangeRate":-0.006135},{"month":11,"riseRate":0.529412,"avgChangeRate":0.041578},{"month":12,"riseRate":0.5,"avgChangeRate":0.045405}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction